Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Accumulated Depreciation: 2018-2024

Historic Accumulated Depreciation for Bicycle Therapeutics (BCYC) over the last 5 years, with Jun 2024 value amounting to $16.6 million.

  • Bicycle Therapeutics' Accumulated Depreciation rose 59.03% to $16.6 million in Q2 2024 from the same period last year, while for Jun 2024 it was $16.6 million, marking a year-over-year increase of 59.03%. This contributed to the annual value of $13.4 million for FY2023, which is 70.33% up from last year.
  • As of Q2 2024, Bicycle Therapeutics' Accumulated Depreciation stood at $16.6 million, which was up 11.14% from $14.9 million recorded in Q1 2024.
  • Bicycle Therapeutics' 5-year Accumulated Depreciation high stood at $16.6 million for Q2 2024, and its period low was $2.8 million during Q1 2020.
  • In the last 3 years, Bicycle Therapeutics' Accumulated Depreciation had a median value of $9.6 million in 2023 and averaged $10.0 million.
  • Data for Bicycle Therapeutics' Accumulated Depreciation shows a peak YoY skyrocketed of 101.58% (in 2023) over the last 5 years.
  • Quarterly analysis of 5 years shows Bicycle Therapeutics' Accumulated Depreciation stood at $4.0 million in 2020, then grew by 19.05% to $4.8 million in 2021, then surged by 63.81% to $7.9 million in 2022, then surged by 70.33% to $13.4 million in 2023, then surged by 59.03% to $16.6 million in 2024.
  • Its Accumulated Depreciation stands at $16.6 million for Q2 2024, versus $14.9 million for Q1 2024 and $13.4 million for Q4 2023.